ZA201404269B - 2-(pyridin-2yl)-1,7 -diaza-spiro[4.4]nonane-6-one compound as voltage-gated sodium channels modulator - Google Patents
2-(pyridin-2yl)-1,7 -diaza-spiro[4.4]nonane-6-one compound as voltage-gated sodium channels modulatorInfo
- Publication number
- ZA201404269B ZA201404269B ZA2014/04269A ZA201404269A ZA201404269B ZA 201404269 B ZA201404269 B ZA 201404269B ZA 2014/04269 A ZA2014/04269 A ZA 2014/04269A ZA 201404269 A ZA201404269 A ZA 201404269A ZA 201404269 B ZA201404269 B ZA 201404269B
- Authority
- ZA
- South Africa
- Prior art keywords
- diaza
- nonane
- spiro
- pyridin
- compound
- Prior art date
Links
- -1 2-(pyridin-2yl)-1,7 -diaza-spiro[4.4]nonane-6-one compound Chemical class 0.000 title 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 title 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579613P | 2011-12-22 | 2011-12-22 | |
| GBGB1122113.2A GB201122113D0 (en) | 2011-12-22 | 2011-12-22 | Novel compounds |
| PCT/GB2012/053233 WO2013093496A1 (en) | 2011-12-22 | 2012-12-21 | 2 - (pyridin- 2yl) - 1, 7 -diaza-spiro [4.4] nonane- 6 -one compound as voltage-gated sodium channels modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201404269B true ZA201404269B (en) | 2016-06-29 |
Family
ID=45572877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/04269A ZA201404269B (en) | 2011-12-22 | 2014-06-10 | 2-(pyridin-2yl)-1,7 -diaza-spiro[4.4]nonane-6-one compound as voltage-gated sodium channels modulator |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9303032B2 (enExample) |
| EP (2) | EP2797922B1 (enExample) |
| JP (2) | JP2015502394A (enExample) |
| KR (1) | KR20140113692A (enExample) |
| CN (1) | CN104271581B (enExample) |
| AU (1) | AU2012356386A1 (enExample) |
| BR (1) | BR112014014940A2 (enExample) |
| CA (1) | CA2858938C (enExample) |
| EA (1) | EA026500B1 (enExample) |
| ES (1) | ES2581327T3 (enExample) |
| GB (1) | GB201122113D0 (enExample) |
| HK (2) | HK1203501A1 (enExample) |
| IL (1) | IL233215A0 (enExample) |
| IN (1) | IN2014MN01469A (enExample) |
| MX (1) | MX2014007637A (enExample) |
| SG (1) | SG11201403356YA (enExample) |
| WO (2) | WO2013093497A1 (enExample) |
| ZA (1) | ZA201404269B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| RU2650523C1 (ru) * | 2017-07-24 | 2018-04-16 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Производное пиридоксина для лечения эпилепсии |
| KR20200068678A (ko) * | 2017-10-10 | 2020-06-15 | 바이오젠 인크. | 스피로 유도체를 제조하기 위한 공정 |
| MX389626B (es) | 2017-11-17 | 2025-03-20 | Cellix Bio Private Ltd | Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. |
| CN113563258A (zh) * | 2021-07-29 | 2021-10-29 | 派普医药(江苏)有限公司 | 一种4-溴-2-(二氟甲基)-5-甲基吡啶的制备方法 |
| WO2023044364A1 (en) | 2021-09-15 | 2023-03-23 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
| TW202322794A (zh) * | 2021-09-24 | 2023-06-16 | 加拿大商再諾製藥公司 | 做為鈉通道活化劑之吡啶基衍生物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| RO119946B1 (ro) | 1995-02-13 | 2005-06-30 | G.D. Searle & Co. | Derivaţi de izoxazol, utilizaţi pentru tratamentul inflamaţiilor |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| BR9708574A (pt) | 1996-04-12 | 1999-08-03 | Searle & Co | Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2 |
| DE69724788T2 (de) | 1996-07-18 | 2004-08-05 | Merck Frosst Canada & Co., Halifax | Substituierte pyridine als selektive cyclooxygenase inhibitoren |
| CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| CA2303152A1 (en) | 1997-09-05 | 1999-03-18 | Glaxo Group Limited | 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors |
| CN1263755C (zh) | 1998-11-03 | 2006-07-12 | 葛兰素集团有限公司 | 作为选择性cox－2抑制剂的吡唑并吡啶衍生物 |
| US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
| DE69915519T2 (de) | 1999-02-27 | 2005-02-03 | Glaxo Group Ltd., Greenford | Pyrazolopyridine |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| SE0302811D0 (sv) * | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| EP1943216B1 (en) | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| GB0520578D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
| US8143306B2 (en) | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| US7505330B2 (en) * | 2006-08-31 | 2009-03-17 | Micron Technology, Inc. | Phase-change random access memory employing read before write for resistance stabilization |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| JP2010516734A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物 |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| PT2477964E (pt) | 2009-09-14 | 2015-06-04 | Convergence Pharmaceuticals | Processo para a preparação de derivados de alfa-carboxamida |
| AU2010306768B2 (en) * | 2009-10-14 | 2016-08-04 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
-
2011
- 2011-12-22 GB GBGB1122113.2A patent/GB201122113D0/en not_active Ceased
-
2012
- 2012-12-21 US US14/365,391 patent/US9303032B2/en not_active Expired - Fee Related
- 2012-12-21 CA CA2858938A patent/CA2858938C/en active Active
- 2012-12-21 WO PCT/GB2012/053234 patent/WO2013093497A1/en not_active Ceased
- 2012-12-21 US US14/365,372 patent/US9376436B2/en not_active Expired - Fee Related
- 2012-12-21 ES ES12810416.3T patent/ES2581327T3/es active Active
- 2012-12-21 JP JP2014548201A patent/JP2015502394A/ja active Pending
- 2012-12-21 HK HK15104075.3A patent/HK1203501A1/xx unknown
- 2012-12-21 BR BR112014014940A patent/BR112014014940A2/pt not_active Application Discontinuation
- 2012-12-21 IN IN1469MUN2014 patent/IN2014MN01469A/en unknown
- 2012-12-21 MX MX2014007637A patent/MX2014007637A/es unknown
- 2012-12-21 EP EP12810416.3A patent/EP2797922B1/en not_active Not-in-force
- 2012-12-21 EA EA201491251A patent/EA026500B1/ru unknown
- 2012-12-21 KR KR1020147019965A patent/KR20140113692A/ko not_active Withdrawn
- 2012-12-21 SG SG11201403356YA patent/SG11201403356YA/en unknown
- 2012-12-21 EP EP12810417.1A patent/EP2794612B1/en not_active Not-in-force
- 2012-12-21 JP JP2014548202A patent/JP2015502395A/ja active Pending
- 2012-12-21 HK HK15103930.0A patent/HK1203492A1/xx unknown
- 2012-12-21 AU AU2012356386A patent/AU2012356386A1/en not_active Abandoned
- 2012-12-21 CN CN201280070485.0A patent/CN104271581B/zh not_active Expired - Fee Related
- 2012-12-21 WO PCT/GB2012/053233 patent/WO2013093496A1/en not_active Ceased
-
2014
- 2014-06-10 ZA ZA2014/04269A patent/ZA201404269B/en unknown
- 2014-06-18 IL IL233215A patent/IL233215A0/en unknown
-
2016
- 2016-02-25 US US15/053,445 patent/US20160185758A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015502395A (ja) | 2015-01-22 |
| CN104271581A (zh) | 2015-01-07 |
| US20150225400A1 (en) | 2015-08-13 |
| EP2794612A1 (en) | 2014-10-29 |
| HK1203501A1 (en) | 2015-10-30 |
| IL233215A0 (en) | 2014-08-31 |
| US9376436B2 (en) | 2016-06-28 |
| US9303032B2 (en) | 2016-04-05 |
| AU2012356386A1 (en) | 2014-07-10 |
| GB201122113D0 (en) | 2012-02-01 |
| WO2013093496A1 (en) | 2013-06-27 |
| EP2797922A1 (en) | 2014-11-05 |
| IN2014MN01469A (enExample) | 2015-04-17 |
| SG11201403356YA (en) | 2014-07-30 |
| EP2794612B1 (en) | 2016-04-06 |
| KR20140113692A (ko) | 2014-09-24 |
| WO2013093497A1 (en) | 2013-06-27 |
| ES2581327T3 (es) | 2016-09-05 |
| EA201491251A1 (ru) | 2014-11-28 |
| BR112014014940A2 (pt) | 2017-06-13 |
| US20140350040A1 (en) | 2014-11-27 |
| MX2014007637A (es) | 2014-09-26 |
| US20160185758A1 (en) | 2016-06-30 |
| HK1203492A1 (en) | 2015-10-30 |
| JP2015502394A (ja) | 2015-01-22 |
| EP2797922B1 (en) | 2016-04-06 |
| CN104271581B (zh) | 2016-08-31 |
| EA026500B1 (ru) | 2017-04-28 |
| CA2858938C (en) | 2020-03-10 |
| CA2858938A1 (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233215A0 (en) | Compound 2-(pyridine-2-yl)-7,1-diaza-spiro[4.4]nonane-6-one as a modulator of voltage-gated sodium channels | |
| SMT202100652T1 (it) | Composti di 2-(2,4,5-anilino-sostituita) pirimidina | |
| ZA201206440B (en) | [5,6]heterocyclic compound | |
| EP2875029B8 (en) | 5,5-heteroaromatic anti-infective compounds | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| EP2699091A4 (en) | 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS | |
| AP2010005408A0 (en) | Fused pyrimidineone compounds as TRPV3 modulators. | |
| EP2723741B8 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| SI2384326T1 (sl) | Pirolo(2,3-d)pirimidinske spojine | |
| SI2694508T1 (sl) | Soli substituiranega 2,3-dihidroimidazo(1,2-C)kinazolina | |
| HK1197066A1 (zh) | Z選擇性關環複分解反應 | |
| AP2012006192A0 (en) | PyrroloÄ2,3-DÜ pyrimidine compounds. | |
| ZA201205788B (en) | 1,2,4-triazine-4-amine derivatives | |
| EP2624698A4 (en) | Furo [3,2-D] PYRIMIDINE COMPOUNDS | |
| AP2011005706A0 (en) | New compounds. | |
| SG11201401342VA (en) | 5,7-substituted-imidazo[1,2-c]pyrimidines | |
| IL232917A0 (en) | History of 5-(3-aminophenyl)-5-alkyl-6,5-dihydro-2h[4,1]oxazin-3-amine | |
| ZA201404074B (en) | 6-difluoromethyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives | |
| PL2531505T3 (pl) | Sposób wytwarzania kompleksów 3,7-diaza-bicyklo[3.3.1]nonanu z metalami | |
| IL227975A0 (en) | 4-aryl-n-phenyl-5,3,1-triazine-2-converted amines | |
| EP2687520A4 (en) | PROCESS FOR PREPARING A 1,2-BENZISOTHIAZOL-3-ON COMPOUND | |
| EP2687519A4 (en) | PROCESS FOR PRODUCING 1,2-BENZISOTHIAZOL-3-ONE COMPOUNDS | |
| EP2883870B8 (en) | Method for producing 1,4-benzoxazine compound | |
| EP2663594A1 (en) | Antioxidant compounds for polyolefin resins | |
| SI2266990T1 (sl) | Spojina 3-fenilpirazolo(5,1-b)tiazola |